Update information
April 2025: In September 2024, recommendation 1.1 was amended. This change was made in error and has been corrected back to the original wording.
September 2024: Recommendation 1.1 has been amended to match the updated marketing authorisation for burosumab, which has also been updated in section 3.1.
ISBN: 978-1-4731-6886-2